[1] | Oliphant CM, Green GM. Quinolones: a comprehensive review. Am Fam Physician. 2002 Feb 1; 65(3): 455-64. PMID: 11858629. |
|
[2] | Bailey RR, Kirk JA, Peddie BA. Norfloxacin-induced rheumatic disease. N Z Med J. 1983 Jul 27; 96(736): 590. PMID: 6223241. |
|
[3] | Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis. 2003 Jun 1; 36(11): 1404-10. Epub 2003 May 20. PMID: 12766835. |
|
[4] | Araujo Eyer-Silva, Walter de, Henrique de Barros Pinto Netto, Jorge Francisco da Cunha Pinto, Fernando Raphael de Almeida Ferry, and Rogério Neves-Motta. “Severe Shoulder Tendinopathy Associated with Levofloxacin.” The Brazilian Journal of Infectious Diseases 16, no. 4 (July 1, 2012): 393-95. |
|
[5] | Childs, Sharon G. Pathogenesis of Tendon Rupture Secondary to Fluoroquinolone Therapy, Orthopaedic Nursing: May-June 2007 - Volume 26 - Issue 3 - p 175-182. |
|
[6] | Lewis T, Cook J. Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature. J Athl Train. 2014; 49(3): 422-427. |
|
[7] | Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol. 1996 Apr; 41(4): 277-84. |
|
[8] | van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ. 2002; 324(7349): 1306-1307. |
|
[9] | Nessrine A, Zahra AF, Taoufik H. Musculoskeletal involvement in sarcoidosis. J Bras Pneumol. 2014; 40(2): 175-182. |
|
[10] | Katie Bechman, Dimitrios Christidis, Sarah Walsh, Surinder S Birring, James Galloway, A review of the musculoskeletal manifestations of sarcoidosis, Rheumatology, Volume 57, Issue 5, May 2018, Pages 777-783. |
|
[11] | Henrie TR, Skedros JG. Sarcoid of the Upper Humerus Found Incidentally on MR Images Obtained for Work-Up of Rotator Cuff Tear Where Compromised Tissue Quality Was a Concern for Surgical Success. Case Rep Radiol. 2018; 2018: 3579527. Published 2018 Jun 10. |
|
[12] | Busto U, Naranjo CA, Sellers EM. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions. Br J Clin Pharmacol. 1982; 13: 223-7. |
|
[13] | Fish, D. N., and A. T. Chow. “The Clinical Pharmacokinetics of Levofloxacin.” Clinical Pharmacokinetics 32, no. 2 (February 1997): 101-19. |
|
[14] | Hall, Mederic M., Jonathan T. Finnoff, and Jay Smith. “Musculoskeletal Complications of Fluoroquinolones: Guidelines and Precautions for Usage in the Athletic Population.” PM&R 3, no. 2 (February 2011): 132-42. |
|
[15] | Lozo, Edith, Kai Riecke, Rudolf Schwabe, Jürgen Vormann, and Ralf Stahlmann. “Synergistic Effect of Ofloxacin and Magnesium Deficiency on Joint Cartilage in Immature Rats.” Antimicrobial Agents and Chemotherapy 46, no. 6 (June 1, 2002): 1755-59. 2002. |
|
[16] | Golomb BA, Koslik HJ, Redd AJ. Fluoroquinolone-induced serious, persistent, multisymptom adverse effects. BMJ Case Rep. 2015; 2015: bcr2015209821. Published 2015 Oct 5. |
|